Morgan Stanley analyst Maxwell Skor assumed coverage of Sana Biotechnology (SANA) with an Overweight rating and $12 price target Six-month data for UP421 in type 1 diabetes show continued cell survival and insulin production without immunosuppression, notes the analyst, who looks forward to an investigational new drug filing for the company’s proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451, as early as next year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Sana Biotechnology Announces Positive Diabetes Study Results
- Sana reports six-month follow-up results from islet cell transplantation study
- Sana Biotechnology Elects Directors at Annual Meeting
- SANA Lawsuit Alert! Class Action Lawsuit Against Sana Biotechnology, Inc.
- Sana Biotechnology Reports Improved Quarterly Loss